JP2009528375A5 - - Google Patents

Download PDF

Info

Publication number
JP2009528375A5
JP2009528375A5 JP2008557453A JP2008557453A JP2009528375A5 JP 2009528375 A5 JP2009528375 A5 JP 2009528375A5 JP 2008557453 A JP2008557453 A JP 2008557453A JP 2008557453 A JP2008557453 A JP 2008557453A JP 2009528375 A5 JP2009528375 A5 JP 2009528375A5
Authority
JP
Japan
Prior art keywords
compound
carbon atoms
hydrogen
hydroxy
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008557453A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009528375A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/062574 external-priority patent/WO2007101060A2/en
Publication of JP2009528375A publication Critical patent/JP2009528375A/ja
Publication of JP2009528375A5 publication Critical patent/JP2009528375A5/ja
Pending legal-status Critical Current

Links

JP2008557453A 2006-02-28 2007-02-22 代謝障害を処置するための化合物 Pending JP2009528375A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77767806P 2006-02-28 2006-02-28
PCT/US2007/062574 WO2007101060A2 (en) 2006-02-28 2007-02-22 Compounds for the treatment of metabolic disorders

Publications (2)

Publication Number Publication Date
JP2009528375A JP2009528375A (ja) 2009-08-06
JP2009528375A5 true JP2009528375A5 (enExample) 2011-03-03

Family

ID=38459732

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008557453A Pending JP2009528375A (ja) 2006-02-28 2007-02-22 代謝障害を処置するための化合物

Country Status (13)

Country Link
US (2) US20100227901A1 (enExample)
EP (1) EP1988772B1 (enExample)
JP (1) JP2009528375A (enExample)
KR (1) KR20080098615A (enExample)
CN (1) CN101394738A (enExample)
AT (1) ATE530066T1 (enExample)
AU (1) AU2007220868B2 (enExample)
CA (1) CA2642662A1 (enExample)
IL (1) IL193321A0 (enExample)
MX (1) MX2008011022A (enExample)
NZ (1) NZ570100A (enExample)
WO (1) WO2007101060A2 (enExample)
ZA (1) ZA200806444B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3489257A1 (en) 2004-07-23 2019-05-29 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
EP2781222B1 (en) 2005-11-23 2017-08-02 Acceleron Pharma, Inc. Activin-actriia antagonists in use for promoting bone growth
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
CN101378740A (zh) * 2006-02-02 2009-03-04 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
CA2677007A1 (en) 2007-02-01 2008-08-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
EP2481415B1 (en) 2007-02-09 2019-09-11 Acceleron Pharma Inc. Pharmaceutical compositions comprising Activin-ActRIIA antagonists
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP2010539236A (ja) 2007-09-18 2010-12-16 アクセルロン ファーマ, インコーポレイテッド アクチビン−ActRIIa拮抗薬およびFSH分泌を低減または阻害するための使用
JP5496913B2 (ja) * 2008-01-15 2014-05-21 ウェルスタット セラピューティクス コーポレイション 代謝異常の治療のための化合物
TWI626945B (zh) 2008-08-14 2018-06-21 艾瑟勒朗法瑪公司 使用gdf阱以增加紅血球水平
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
JP5912078B2 (ja) 2009-06-08 2016-04-27 アクセルロン ファーマ, インコーポレイテッド 熱発生性脂肪細胞を増加させるための方法
EP3290439B1 (en) 2009-06-12 2020-09-02 Acceleron Pharma Inc. Truncated actriib-fc fusion proteins
WO2011056896A1 (en) * 2009-11-03 2011-05-12 Acceleron Pharma Inc. Methods for treating fatty liver disease
EP3332796A1 (en) 2009-11-17 2018-06-13 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
KR20130132824A (ko) 2010-11-08 2013-12-05 악셀레론 파마 인코포레이티드 Actriia 결합제 및 이의 용도
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8500260B2 (en) 2011-04-27 2013-08-06 Xerox Corporation Ink compositions incorporating substituted oxazoline compounds or substituted oxazoline derivatives
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US10195249B2 (en) 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
MA40008A (fr) 2014-06-13 2021-05-05 Acceleron Pharma Inc Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
TWI730949B (zh) 2014-12-03 2021-06-21 美商西建公司 活化素-actrii拮抗劑及治療貧血之用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4824843A (en) * 1987-06-25 1989-04-25 Warner-Lambert Company Substituted amide inhibitors of cholesterol absorption
JP3906935B2 (ja) * 1995-12-18 2007-04-18 杏林製薬株式会社 N−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
US6555536B2 (en) * 2000-05-12 2003-04-29 Ortho-Mcneil Pharmaceutical, Inc. Biologically active 4H-benzo [1,4]oxazin-3-ones
KR100965201B1 (ko) * 2001-06-12 2010-06-24 웰스테트 테라퓨틱스 코포레이션 대사 질환의 치료용 화합물
AU2003286728A1 (en) * 2002-11-01 2004-06-07 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
ES2530235T3 (es) * 2003-02-13 2015-02-27 Wellstat Therapeutics Corporation Compuestos para el tratamiento de trastornos metabólicos
KR101127390B1 (ko) * 2003-04-15 2012-03-23 웰스태트 테러퓨틱스 코포레이션 대사 질환의 치료용 화합물
EP1618086B1 (en) * 2003-04-22 2009-12-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2004098496A2 (en) * 2003-04-30 2004-11-18 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
NZ545268A (en) * 2003-08-20 2009-05-31 Wellstat Therapeutics Corp Compounds for the treatment of metabolic disorders

Similar Documents

Publication Publication Date Title
JP2009531280A5 (enExample)
JP2009528275A5 (enExample)
JP2009537559A5 (enExample)
CA2513092A1 (en) Compounds for the treatment of metabolic disorders
CA2521621A1 (en) Compounds for the treatment of metabolic disorders
JP2006524252A5 (enExample)
CA2522738A1 (en) Compounds for the treatment of metabolic disorders
JP6238460B2 (ja) 脂質異常症治療剤
CA2521589A1 (en) Compounds for the treatment of metabolic disorders
RU2008123000A (ru) Соединения для лечения метаболических нарушений
JP2011519865A5 (enExample)
JP2004524312A5 (enExample)
EP1988772A2 (en) Compounds for the treatment of metabolic disorders
JP2009530398A5 (enExample)
RU2004105956A (ru) Новые производные винилкарбоновых кислот и их применение в качестве антидиабетических средств и т.п.
RU2010141823A (ru) Соединения и способ снижения мочевой кислоты
CN103102348B (zh) 噁二唑类化合物及其制备方法、药物组合物及其用途
JP2005526696A5 (enExample)
JP2009524686A5 (enExample)
RU2006108572A (ru) Соединения для лечения метаболических нарушений
CN1159305C (zh) 新的2-(n-氰基亚氨基)噻唑烷-4-酮衍生物
JP2004508399A5 (enExample)
JP2009528997A5 (enExample)
EP1868595B1 (en) Compounds for the treatment of metabolic disorders
EP1569904B1 (en) Substituted arylalcanoic acid derivatives as ppar pan agonists with potent antihyperglycemic and antihyperlipidemic activity